###### Key questions

What is already known about this subject?
=========================================

-   The choice of treatment in patients with metastatic colorectal cancer (mCRC) is generally influenced by tumour characteristics and patient factors, as well as treatment characteristics such as tolerability, efficacy and quality-of-life effects. Trifluridine/tipiracil is indicated in pretreated patients with mCRC, based on results of the pivotal Randomised, Double-blind, Phase 3 Study of trifluridine tipiracil (FTD/TPI) plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapies (RECOURSE) trial, which demonstrated significantly improved overall survival (OS) compared with placebo with a manageable safety profile.

What does this study add?
=========================

-   In RECOURSE, classification of patients as having good prognostic characteristics (GPC, defined as those with low tumour burden (\<3 metastatic sites at randomisation) and less aggressive disease (≥18 months from diagnosis of first metastasis at randomisation)) identified a subgroup of patients with improved OS and progression-free survival with trifluridine/tipiracil compared with patients with poor prognostic characteristics treated with trifluridine/tipiracil and GPC patients treated with placebo.

How might this impact on clinical practice?
===========================================

-   Low tumour burden and indolent disease were shown to be factors of good prognosis in late-line mCRC, with these patients experiencing longer time on treatment and greater OS. This suggests that these patients could be candidates to receive further lines of therapy post trifluridine/tipiracil.

Introduction {#s1}
============

Inclusion of new therapeutic options into the current treatment landscape in metastatic colorectal cancer (mCRC) has led to an increased survival in the last couple of decades.[@R1] First-line treatment of patients typically involves the use of vascular endothelial growth factor (VEGF)- or epidermal growth factor receptor (EGFR)-targeted agents (eg, bevacizumab, cetuximab, panitumumab) to fluoropyrimidine-based (fluorouracil or capecitabine) chemotherapy regimens, depending on the presence or absence of *RAS* mutation-positive disease.[@R2] In the USA, immunotherapies (nivolumab±ipilimumab or pembrolizumab) are also recommended for the treatment of patients with mismatch repair deficient or microsatellite instability-high disease.[@R4] In the second-line setting, VEGF-targeted treatments (eg, aflibercept, ramucirumab) can also be used in combination with chemotherapy.[@R2] The optimal chemotherapeutic regimen for use beyond third line remains unclear, where resistant/refractory disease and residual toxicity potentially limit the treatment options with only two possible candidates at present.[@R5]

The general condition and performance status of a patient are strong prognostic and predictive factors for mCRC treatment.[@R2] Fitter patients are typically assigned to a more intensive treatment approach (ie, a combination of 2--3 cytotoxic agents with a biological agent) than less fit patients.[@R2] The choice of treatment in the metastatic setting is generally influenced by tumour characteristics (tumour burden, localisation and biology), patient characteristics (age, Eastern Cooperative Oncology Group performance status (ECOG PS), organ function and comorbidities) and treatment characteristics (efficacy, toxicity profile, administration and quality of life (QoL) effects).[@R2]

The proportion of patients with mCRC receiving active treatment decreases from line to line, leaving more than half of patients who received an active treatment in the first line without treatment in the third-line setting, even in randomised clinical trials (in FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer only 43% of patients reached third line).[@R6] Data from the USA indicate that only 53% of patients receiving a first line of treatment move into the second line, 28% move to the third line and only 13% will receive a fourth line of treatment.[@R7] Being unable to receive a subsequent line of treatment therefore appears to have a negative impact on the patient's survival.

Trifluridine/tipiracil (FTD/TPI, Lonsurf) is indicated for the treatment of adult patients with mCRC who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-based, oxaliplatin-based and irinotecan-based chemotherapies, anti-VEGF agents and anti-EGFR agents for eligible patient (*RAS* wild type). Combination of tipiracil hydrochloride with the nucleoside metabolic inhibitor trifluridine improves its bioavailability by inhibiting its catabolism by thymidine phosphorylase.[@R8] The relatively limited non-haematological toxicity of trifluridine/tipiracil makes it a good option in the third-line and refractory settings.[@R2]

In the pivotal phase III Randomised, Double-blind, Phase 3 Study of trifluridine tipiracil (FTD/TPI) plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapies (RECOURSE) trial conducted in 800 patients with mCRC eligible for treatment in the third line and beyond, treatment with trifluridine/tipiracil versus placebo extended overall survival (median OS 7.1 vs 5.3 months; HR 0.68, p\<0.001) and progression-free survival (median PFS 2.0 vs 1.7 months; HR 0.48, p\<0.001).[@R10] This effect was shown in all subgroups regardless of age, ECOG PS (0--1), geographical region, race and *KRAS* mutational status.[@R10] Furthermore, trifluridine/tipiracil was well tolerated, with few serious adverse events (AEs) reported; haematological toxicities were the most frequently observed AEs.[@R10] Also, time to deterioration of ECOG PS to ≥2 was significantly improved (median 5.7 vs 4.0 months; HR 0.66, p\<0.001)[@R10] with 84% of patients treated with trifluridine/tipiracil remaining at PS 0--1 at discontinuation.[@R11] Remaining at ECOG PS 0--1 is important as it could allow patients to further benefit from subsequent therapy and potentially extend their survival. In RECOURSE, 57.8% and 26.6% of patients treated with trifluridine/tipiracil remained alive at 6 and 12 months, respectively, in the refractory setting. In the post hoc analysis described here, we set out to explore other factors that could extend survival in the RECOURSE population. For the purposes of our exploratory analysis, we defined the characteristics of good prognosis as low tumour burden (\<3 metastatic sites by Response Evaluation Criteria in Solid Tumors (RECIST) evaluation at randomisation) and less aggressive/indolent disease (≥18 months from diagnosis of first metastasis to randomisation), which are known to be strong prognostic factors in patients with mCRC with good ECOG PS.[@R12] Our ultimate aim is to explore how clinicians can better predict individual treatment outcomes and support treatment selection through the continuum of care.

Materials and methods {#s2}
=====================

Study design and patients {#s2-1}
-------------------------

The study design and methodology of the RECOURSE trial (ClinicalTrials.gov number, NCT01607957) have been previously published.[@R10] In brief, RECOURSE was a phase III, randomised, double-blind, placebo-controlled study comparing the efficacy and safety of trifluridine/tipiracil plus best supportive care with those of placebo plus best supportive care.[@R10] This study included patients with metastatic biopsy-proven/documented adenocarcinoma of the colon or rectum who were previously treated with ≥2 standard chemotherapy regimens or who had tumour progression within 3 months of their most recent chemotherapy or who had clinically significant AEs precluding readministration of standard chemotherapies. Patients were randomised 2:1 to trifluridine/tipiracil 35 mg/m^2^ two times a day on days 1--5 and 8--12 every 4 weeks or matching placebo.[@R10] Randomisation was stratified according to *KRAS* mutation status (wild type vs mutant), time from diagnosis of first metastasis to randomisation (\<18 vs ≥18 months) and geographical region (Japan vs USA, European Union and Australia).[@R10] All patients had adequate organ function and were ECOG PS of 0--1 at inclusion.[@R10] The primary endpoint of the study was OS and secondary endpoints included PFS, objective response rate, clinical benefit rate and safety.[@R10]

Patient subgroups {#s2-2}
-----------------

In examining the effects of prognostic factors on treatment outcomes in the current analysis, several subgroups of RECOURSE patients were considered. Patients from RECOURSE (n=800) were divided according to good prognostic characteristics (GPC) and poor prognostic characteristics (PPC). Good prognosis was considered to be defined by low tumour burden (\<3 metastatic sites by RECIST tumour evaluation at randomisation) and less aggressive/indolent disease (≥18 months from diagnosis of first metastasis to randomisation).[@R12] Of the GPC subgroup (n=386), 261 (67.7%) patients received trifluridine/tipiracil and 125 received placebo. The remaining patients were included in the complementary PPC subgroup (n=414); of these, 273 received trifluridine/tipiracil and 141 received placebo.

Analysis outcomes {#s2-3}
-----------------

OS and PFS in the GPC subgroup were compared with those in the PPC subgroup. These subgroups were then analysed according to other tumour and patient characteristics, that is, metastatic site at randomisation for those sites present in \>10% of the population (liver, lung, lymph, or peritoneum), ECOG PS (0 vs 1), *KRAS* mutation status (wild type vs mutant) and age (\<65 vs ≥65 years). OS and PFS with trifluridine/tipiracil were compared with placebo, and were analysed according to prognostic subgroups within each of the two arms. Finally, the effect of prognostic classification of patients on ECOG PS deterioration was analysed for all patients and subgroups.

Statistical methods {#s2-4}
-------------------

Demographic and baseline characteristics of patients were summarised by treatment arm and subgroups using descriptive statistics (n, mean, SD, median, minimum and maximum) and/or frequency distributions, as appropriate.

The differences in OS, PFS and time to ECOG PS deterioration between trifluridine/tipiracil and placebo patients (or between subgroups of patients in a specific arm of treatment) were assessed using the stratified log-rank test (stratification factors used for the randomisation) from a Cox proportional hazards model. For each arm (or each subgroup), survival was summarised using Kaplan-Meier curves and was further characterised in terms of the median with the corresponding two-sided 95% CIs.

Results {#s3}
=======

Patients {#s3-1}
--------

Baseline patient demographics and clinical characteristics were generally similar between GPC and PPC patients ([table 1](#T1){ref-type="table"}). In the trifluridine/tipiracil arm, slight imbalances were seen in ECOG PS (8.1% more GPC than PPC patients had an ECOG PS of 0) and *KRAS* status (10.4% more GPC than PPC patients were *KRAS* wild type). Also, 21.4% more GPC than PPC patients had received ≥4 prior regimens. Among the PPC group treated with trifluridine/tipiracil, 59.3% of patients had ≥18 months from diagnosis of first metastasis to randomisation, but had ≥3 metastatic sites, and 23.1% of patients had \<3 metastatic sites, but \<18 months from diagnosis of first metastasis. Similar differences were observed in the placebo arm, with the exception of *KRAS* status, which was comparable in the GPC and PPC subgroups.

###### 

Baseline patient demographics and clinical characteristics, according to prognosis

                                              Trifluridine/tipiracil   Placebo                    
  ------------------------------------------- ------------------------ ------------ ------------- ------------
  Median age, years                           64.0                     62.0         63.0          64.0
  Patient age, n (%)                                                                              
   \<65 years                                 137 (52.5)               163 (59.7)   72 (57.6)     76 (53.9)
   65 to \<75 years                           105 (40.2)               93 (34.1)    43 (34.4)     51 (36.2)
   ≥75 years                                  19 (7.3)                 17 (6.2)     10 (8.0)      14 (9.9)
  Gender, n (%)                                                                                   
   Females                                    97 (37.2)                111 (40.7)   47 (37.6)     54 (38.3)
   Male                                       164 (62.8)               162 (59.3)   78 (62.4)     87 (61.7)
  Ethnicity, n (%)                                                                                
   Asian                                      91 (34.9)                93 (34.1)    43 (34.4)     51 (36.2)
   Other                                      170 (65.1)               180 (65.9)   82 (65.6)     90 (63.8)
  ECOG PS, n (%)                                                                                  
   0                                          158 (60.5)               143 (52.4)   77 (61.6)     70 (49.6)
   1                                          103 (39.5)               130 (47.6)   48 (38.4)     71 (50.4)
  *KRAS* status, n (%)                                                                            
   Mutant                                     119 (45.6)               153 (56.0)   64 (51.2)     71 (50.4)
   Wild type                                  142 (54.4)               120 (44.0)   61 (48.8)     70 (49.6)
  Time since diagnosis of metastasis, n (%)                                                       
   \<18 months                                0                        111 (40.7)   0             55 (39.0)
   ≥18 months                                 261 (100.0)              162 (59.3)   125 (100.0)   86 (61.0)
  Number of prior regimens, n (%)                                                                 
   2                                          26 (10.0)                69 (25.3)    15 (12.0)     30 (21.3)
   3                                          50 (19.2)                69 (25.3)    18 (14.4)     36 (25.5)
   ≥4                                         185 (70.9)               135 (49.5)   92 (73.6)     75 (53.2)
  Number of metastatic sites, n (%)                                                               
   1--2                                       261 (100.0)              63 (23.1)    125 (100.0)   28 (19.9)
   ≥3                                         0                        210 (76.9)   0             113 (80.1)
  Site of metastatic lesion, n (%)†                                                               
   Liver                                      164 (62.8)               238 (87.2)   69 (55.2)     120 (85.1)
   Lung                                       172 (65.9)               219 (80.2)   100 (80.0)    117 (83.0)
   Lymph                                      53 (20.3)                157 (57.5)   32 (25.6)     88 (62.4)
   Peritoneum                                 19 (7.3)                 70 (25.6)    6 (4.8)       41 (29.1)
  Primary site of disease, n (%)                                                                  
   Colon                                      171 (65.5)               167 (61.2)   63 (50.4)     98 (69.5)
   Rectum                                     90 (34.5)                106 (38.8)   62 (49.6)     43 (30.5)

\*Defined as \<3 metastatic sites and ≥18 months since first metastasis.

†Only those in more than 10% of the intent-to-treat population are included (liver, lung, lymph and peritoneum).

ECOG PS, Eastern Cooperative Oncology Group performance status; GPC, good prognostic characteristics; PPC, poor prognostic characteristics.

Treatment {#s3-2}
---------

Among trifluridine/tipiracil-treated patients, those in the GPC group received more treatment cycles (mean (SD) 4.1 (2.9)) compared with patients in the PPC group (mean (SD) 2.8 (2.0); [online supplementary table S1](#SP1){ref-type="supplementary-material"}). A higher proportion of GPC patients than PPC patients receiving trifluridine/tipiracil had a dose delay (53.6% vs 38.6%, respectively) or dose reduction (18.0% vs 9.6%, respectively), which is consistent with a longer duration of treatment ([online supplementary table S1](#SP1){ref-type="supplementary-material"}). However, median dose intensity in the first four cycles was high (≥80%) and did not differ markedly between the groups (cycle 1: 94.3% in the GPC group and 95.2% the PPC group; cycle 2: 89.7% and 93.0%, respectively; cycle 3: 82.4% and 87.4%, respectively; cycle 4: 84.0% and 88.3%, respectively).
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The effect of good versus poor prognosis classifications on survival {#s3-3}
--------------------------------------------------------------------

Survival curves for the GPC versus PPC subgroups are shown in [figure 1](#F1){ref-type="fig"}. Median OS was longer in the GPC subgroup than the PPC subgroup for both trifluridine/tipiracil (9.3 vs 5.3 months; HR (95% CI) 0.46 (0.37 to 0.57), p\<0.0001, [figure 1A](#F1){ref-type="fig"}) and placebo (6.8 vs 4.4 months; HR (95% CI) 0.55 (0.42 to 0.73), p\<0.0001, [figure 1B](#F1){ref-type="fig"}). Rates of 6 month OS (71.7% and 53.9% in GPC, and 44.4% and 34.1% in PPC for trifluridine/tipiracil and placebo, respectively) and 12 month OS (37.5% and 25.2% in GPC, and 15.3% and 10.9% in PPC for trifluridine/tipiracil and placebo, respectively) were also higher in GPC subgroups compared with PPC subgroups. Median PFS with trifluridine/tipiracil was also longer in the GPC subgroup versus the PPC subgroup (3.3 vs 1.9 months; HR (95% CI) 0.56 (0.46 to 0.67), p\<0.0001); respective values for GPC versus PPC in the placebo arm were 1.8 versus 1.7 months (HR 0.79, p=0.0699). PFS at 3 and 6 months in the PPC subgroup was 31.0% and 7.9% for trifluridine/tipiracil and 11.6% and 0.9% for placebo, respectively. In the GPC subgroup, these were 51.1% and 22.4% with trifluridine/tipiracil, and 22.4% and 1.9% with placebo, respectively.

![Overall survival (OS) for the good prognostic characteristics (GPC) and poor prognostic characteristics (PPC) subgroups in patients receiving (A) trifluridine/tipiracil or (B) placebo. ^a^p\<0.001 (one sided). ^b^p\<0.001 (two sided). FTD/TPI, trifluridine/tipiracil; mOS, median overall survival; NR, not reached.](esmoopen-2020-000752f01){#F1}

Effects of good prognostic factors on the relative efficacy of trifluridine/tipiracil {#s3-4}
-------------------------------------------------------------------------------------

Median OS was prolonged with trifluridine/tipiracil versus placebo in both subgroups, but to a greater extent in the GPC subgroup than in the PPC subgroup ([figure 2A](#F2){ref-type="fig"}). Similarly, median PFS was prolonged with trifluridine/tipiracil versus placebo in both subgroups, with the greatest magnitude of benefit observed in the GPC patients ([figure 2B](#F2){ref-type="fig"}).

![(A) Overall survival (OS), (B) progression-free survival (PFS) and (C) time to Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2 with trifluridine/tipiracil versus placebo in the good prognostic characteristics (GPC; n=386) and poor prognostic characteristics (PPC; n=414) subgroups. FTD/TPI, trifluridine/tipiracil; mOS, median overall survival.](esmoopen-2020-000752f02){#F2}

Analysis of prognostic factors {#s3-5}
------------------------------

The effect of various prognostic factors on median OS and PFS is shown in [table 2](#T2){ref-type="table"}; their effect on 6-month and 12-month OS, and 3-month, 6-month, and 9-month PFS is shown in [online supplementary tables 2 and 3](#SP1){ref-type="supplementary-material"}. For both trifluridine/tipiracil and placebo, the GPC subgroup had better median OS and PFS than the PPC subgroup, irrespective of patient age (≥65 vs \<65 years), ECOG PS (0 vs 1), *KRAS* mutation status (mutant vs wild type) and liver metastases (yes vs no).

###### 

The effect of various prognostic factors on median overall survival (OS) and progression-free survival (PFS)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
                 Number of patients\        Median survival, months   HR (95% CI)            Number of patients\   Median survival, months   HR (95% CI)
                 FTD/TPI /placebo                                                            FTD/TPI/placebo                                 
  -------------- -------------------------- ------------------------- ---------------------- --------------------- ------------------------- ---------------------
  **OS**                                                                                                                                     

                 No liver metastases        Liver metastases                                                                                 

  GPC subgroup   n=97/n=56                  16.4 vs 8.6               0.47 (0.29 to 0.77)    n=164/n=69            7.7 vs 4.7                0.61 (0.44 to 0.85)

  PPC subgroup   n=35/n=21                  7.6 vs 7.2                0.70 (0.35 to 1.37)    n=238/n=120           5.0 vs 3.7                0.7 (0.55 to 0.89)

                 No lung metastases         Lung metastases                                                                                  

  GPC subgroup   n=89/n=25                  9.2 vs 7.3                0.77 (0.45 to 1.31)    n=172/n=100           9.8 vs 6.3                0.57 (0.41 to 0.78)

  PPC subgroup   n=54/n=24                  5.0 vs 3.7                0.93 (0.52 to 1.64)    n=219/n=117           5.3 vs 4.4                0.71 (0.55 to 0.91)

                 No lymph metastases        Lymph metastases                                                                                 

  GPC subgroup   n=208/n=93                 9.2 vs 6.3                0.65 (0.48 to 0.88)    n=53/n=32             10.3 vs 6.9               0.53 (0.30 to 0.93)

  PPC subgroup   n=116/n=53                 5.0 vs 4.2                0.75 (0.52 to 1.08)    n=157/n=88            5.4 vs 4.5                0.72 (0.54 to 0.97)

                 No peritoneal metastases   Peritoneal metastases                                                                            

  GPC subgroup   n=242/n=119                9.1 vs 6.8                0.66 (0.51 to 0.87)    n=19/n=6              14.2 vs 5.6               0.23 (0.06 to 0.90)

  PPC subgroup   n=203/n=100                5.3 vs 4.7                0.74 (0.57 to 0.97)    n=70/n=41             4.9 vs 3.3                0.70 0.45 to 1.07)

                 ECOG PS=0                  ECOG PS=1                                                                                        

  GPC subgroup   n=158/n=77                 10.5 vs 7.1               0.66 (0.47 to 0.94)    n=103/n=48            8.0 vs 5.9                0.54 (0.36 to 0.81)

  PPC subgroup   n=143/n=70                 6.7 vs 5.2                0.77 (0.55 to 1.07)    n=130/n=71            4.2 vs 3.5                0.69 (0.50 to 0.95)

                 Age \<65 years             Age≥65 years                                                                                     

  GPC subgroup   n=137/n=72                 9.8 vs 6.9                0.64 (0.45 to 0.92)    n=124/n=53            9.1 vs 6.3                0.57 (0.39 to 0.84)

  PPC subgroup   n=163/n=76                 4.9 vs 5.0                0.80 (0.59 to 1.09)    n=110/n=65            5.6 vs 3.9                0.68 (0.48 to 0.97)

                 *KRAS* wild type           *KRAS* mutant                                                                                    

  GPC subgroup   n=142/n=61                 9.3 vs 6.9                0.60 (0.42 to 0.86)    n=119/n=64            6.4 vs 4.7                0.61 (0.43 to 0.84)

  PPC subgroup   n=120/n=70                 6.4 vs 4.7                0.61 (0.43 to 0.84)    n=153/n=71            4.7 vs 3.9                0.87 (0.64 to 1.19)

  **PFS**                                                                                                                                    

                 No liver metastases        Liver metastases                                                                                 

  GPC subgroup   n=97/n=56                  5.4 vs 1.9                0.35 (0.24 to 0.52)    n=164/n=69            2.1 vs 1.8                0.32 (0.23 to 0.45)

  PPC subgroup   n=35/n=21                  1.9 vs 1.9                0.84 (0.44 to 1.60)    n=238/n=120           1.9 vs 1.7                0.54 (0.42 to 0.68)

                 No lung metastases         Lung metastases                                                                                  

  GPC subgroup   n=89/n=25                  2.3 vs 1.9                0.57 (0.35 to 0.95)    n=172/n=100           3.6 vs 1.8                0.33 (0.25 to 0.44)

  PPC subgroup   n=54/n=24                  1.8 vs 1.6                0.62 (0.36 to 1.08))   n=219/n=117           1.9 vs 1.7                0.54 (0.42 to 0.69)

                 No lymph metastases        Lymph metastases                                                                                 

  GPC subgroup   n=208/n=93                 3.0 vs 1.8                0.38 (0.29 to 0.49)    n=53/n=32             3.5 vs 1.8                0.40 (0.24 to 0.67)

  PPC subgroup   n=116/n=53                 1.9 vs 1.7                0.49 (0.34 to 0.69)    n=157/n=88            1.9 vs 1.7                0.65 (0.49 to 0.86)

                 No peritoneal metastases   Peritoneal metastases                                                                            

  GPC subgroup   n=242/n=119                2.6 vs 1.8                0.41 (0.32 to 0.52)    n=19/n=6              5.5 vs 1.8                0.19 (0.05 to 0.69)

  PPC subgroup   n=203/n=100                1.9 vs 1.7                0.56 (0.43 to 0.72)    n=70/n=41             1.7 vs 1.6                0.61 (0.40 to 0.93)

                 ECOG PS=0                  ECOG PS=1                                                                                        

  GPC subgroup   n=158/n=77                 3.5 vs 1.8                0.44 (0.32 to 0.59)    n=103/n=48            2.4 vs 1.7                0.33 (0.22 to 0.49)

  PPC subgroup   n=143/n=70                 1.9 vs 1.7                0.53 (0.38 to 0.72)    n=130/n=71            1.8 vs 1.6                0.61 (0.45 to 0.83)

                 Age \<65 years             Age ≥65 years                                                                                    

  GPC subgroup   n=137/n=72                 3.1 vs 1.8                0.42 (0.30 to 0.58)    n=124/n=53            3.5 vs 1.8                0.35 (0.24 to 0.51)

  PPC subgroup   n=163/n=76                 1.8 vs 1.7                0.62 (0.46 to 0.83)    n=110/n=65            1.9 vs 1.7                0.49 (0.35 to 0.69)

                 *KRAS* wild type           *KRAS* mutant                                                                                    

  GPC subgroup   n=142/n=61                 3.3 vs 1.8                0.41 (0.29 to 0.57)    n=119/n=64            3.3 vs 1.8                0.38 (0.27 to 0.53)

  PPC subgroup   n=120/n=70                 1.9 vs 1.7                0.57 (0.41 to 0.79)    n=153/n=71            1.8 vs 1.7                0.57 (0.42 to 0.77)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

Good prognostic characteristics (GPC) were defined as \<3 metastatic sites at randomisation and ≥18 months from first metastasis to randomisation.

FTD/TPI, trifluridine/tipiracil; PPC, poor prognostic characteristics; ECOG PS, Eastern Cooperative Oncology Group performance status.

When analysing the GPC subgroup, the absence of liver metastasis at randomisation (n=153; representing 39.6% of the GPC and 19.1% of the intent-to-treat population) was found to be the best factor of prognosis; further information on this group of patients is available in [online supplementary table S4](#SP1){ref-type="supplementary-material"} and [online supplementary figures S1-S3](#SP1){ref-type="supplementary-material"}. Among GPC patients treated with trifluridine/tipiracil, median OS was 8.7 months longer in patients with no liver metastases compared with those with liver metastases (16.4 vs 7.7 months; [table 2](#T2){ref-type="table"}). The 6-month OS rate in GPC patients treated with trifluridine/tipiracil was 83.4% in those without liver metastases and 64.8% in those with liver metastases; corresponding 12-month OS rates in these groups were 65.1% and 22.1%, respectively ([online supplementary table S2](#SP1){ref-type="supplementary-material"}). Median OS was also longer in patients with no liver metastases compared with those with liver metastases in the trifluridine/tipiracil PPC subgroup (7.6 vs 5.0 months), and both the GPC and PPC subgroups of the placebo arm (8.6 vs 4.7 months, and 7.2 vs 3.7 months, respectively; [table 2](#T2){ref-type="table"}). In the group of PPC patients treated with trifluridine/tipiracil, the 6-month and 12-month OS rates were 62.7% and 36.1%, respectively, in those without liver metastases compared with 41.7% and 12.4%, respectively, in those with liver metastases ([online supplementary table S2](#SP1){ref-type="supplementary-material"}). For the trifluridine/tipiracil and placebo arms, patients with baseline ECOG PS 0 had higher median OS compared with ECOG PS 1 patients in both the GPC and PPC subgroups ([table 2](#T2){ref-type="table"}). In the trifluridine/tipiracil arm, age (\<65 or ≥65 years) and *KRAS* status did not seem to affect the treatment outcome ([table 2](#T2){ref-type="table"}).

Similar results were found for PFS with an effect for all trifluridine/tipiracil GPC and PPC subgroups with median PFS values ranging from 1.7 to 5.4 months ([table 2](#T2){ref-type="table"}). Among GPC patients treated with trifluridine/tipiracil, the 6-month PFS rate was 35.9% in those with no liver metastases compared with 14.5% in those with liver metastases. Corresponding 6-month PFS rates in the PPC group of patients treated with trifluridine/tipiracil were 17.6% and 6.6%, respectively ([online supplementary table S3](#SP1){ref-type="supplementary-material"}). No such effect was observed in the placebo arm, with values ranging 1.6--1.9 months whatever the prognosis at the outset. For almost all subgroups, median PFS was longer and all HRs favoured treatment with trifluridine/tipiracil ([table 2](#T2){ref-type="table"}).

Effects of prognostic classification of patients on ECOG PS {#s3-6}
-----------------------------------------------------------

Data relative to the effect of ECOG PS are presented in [table 3](#T3){ref-type="table"}. The proportion of GPC patients treated with trifluridine/tipiracil with an ECOG PS of 0--1 at treatment discontinuation was 89.1%. Among GPC patients with an ECOG PS of 0 at baseline, 95.2% had not deteriorated beyond a PS of 0--1 at treatment discontinuation. Similarly, among GPC patients with an ECOG PS of 1 at baseline, 78.0% had not deteriorated beyond a PS of 0--1 at treatment discontinuation. The median time to deterioration of ECOG PS to ≥2 in patients receiving trifluridine/tipiracil was 7.8 months in the GPC subgroup and 4.2 months in the PPC subgroup ([figure 2C](#F2){ref-type="fig"}).

###### 

Effects of prognostic classification of patients on Eastern Cooperative Oncology Group performance status (ECOG PS)

                                    Median time to deterioration to ECOG PS ≥2, months   HR (95% CI)   P value               ECOG PS 0--1 at treatment discontinuation, %          
  --------------------------------- ---------------------------------------------------- ------------- --------------------- ---------------------------------------------- ------ ------
  ITT population (n=800)[@R11]      5.7                                                  4.0           0.66 (0.56 to 0.78)   \<0.001                                        84.0   81.0
  Good prognosis patients (n=386)   7.8                                                  4.7           0.53 (0.41 to 0.69)   \<0.0001                                       89.1   83.1
  Poor prognosis patients (n=414)   4.2                                                  3.4           0.80 (0.64 to 1.00)   0.048                                          78.4   75.1

FTD/TPI, trifluridine/tipiracil; ITT, intent to treat.

Tolerability and safety {#s3-7}
-----------------------

The most common AEs in patients receiving trifluridine/tipiracil were nausea, anaemia, neutropenia/neutrophil count decrease, diarrhoea, fatigue and reduced appetite ([online supplementary table S5](#SP1){ref-type="supplementary-material"}). The most common grade ≥3 AEs experienced by patients receiving trifluridine/tipiracil were haematological (anaemia, neutropenia/neutrophil count decrease, white blood cell count decrease). There was no evidence of a higher incidence of AEs in patients with PPC versus GPC in the group receiving trifluridine/tipiracil, but there was a trend towards a higher incidence of AEs in placebo recipients with PPC compared with GPC ([online supplementary table S5](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

The results of our analysis show that patients in the GPC subgroup consistently performed better than those in the PPC subgroup in both the trifluridine/tipiracil and placebo arms. Within the same subgroups, patients treated with trifluridine/tipiracil performed better than placebo. Trifluridine/tipiracil has consistently been shown to provide a significant survival benefit to patients with mCRC refractory to standard therapy with a well-tolerated safety profile in three large-scale, randomised clinical trials.[@R10] A previous subanalysis of RECOURSE showed that trifluridine/tipiracil was more effective than placebo in patients, irrespective of region, age, racial/ethnic differences or *KRAS* mutation status.[@R17] In the current analysis, further categorisation of patients as having good prognosis (using the criteria of \<3 metastatic sites by RECIST tumour evaluation at randomisation and ≥18 months from diagnosis of first metastasis to randomisation[@R12]) identified a subgroup of patients with improved OS and PFS with trifluridine/tipiracil compared with poorer prognosis patients (ie, those with ≥3 metastatic sites and \<18 months from first metastasis). PFS and OS were also improved in GPC patients treated with trifluridine/tipiracil compared with GPC patients who received placebo.

Patients with GPC received more cycles of treatment than patients with PPC, because progression was delayed in this group, which may have contributed to the better survival outcomes. The difference cannot be explained by a difference in dose intensity, since this was high and similar in both the PPC and GPC subgroups of patients receiving trifluridine/tipiracil. In addition, there was no evidence for higher toxicity in the PPC than the GPC group. In fact, the haematological AEs occurred at a slightly higher rate in GPC patients than in PPC patients who received trifluridine/tipiracil, which probably reflects a longer exposure to treatment in the GPC group. More patients in the GPC than in the PPC subgroup had dose delays, which suggests that grade ≥3 haematological AEs were appropriately managed during treatment.

It is thought that the availability of more treatment options for mCRC has contributed to an improvement in OS over the last 20 years.[@R3] Indeed, a retrospective study in elderly patients aged ≥70 years, a patient population more prone to comorbidities, poor performance status and the development of treatment-related toxicity, reported a correlation between OS and the number of treatment lines received.[@R18] Thus, maintaining the general condition and performance status of a patient throughout the continuum of care is of great importance, especially beyond the second line, to ensure patients remain fit, with good QoL.[@R5] Our analysis showed that the majority of patients in the GPC subgroup (89.1%) discontinued treatment with an ECOG PS of 0--1 at the time of disease progression, suggesting that these patients could be candidates to receive further lines of therapy post trifluridine/tipiracil; this is important when sequencing through the continuum of care. This is in line with other analyses indicating preservation of health-related QoL on treatment of patients with mCRC with trifluridine/tipiracil.[@R19]

While the post hoc nature of this analysis limits it to an exploratory analysis, the relatively large number of patients analysed make these data a good tool to estimate the expected outcomes when treating patients with refractory mCRC with trifluridine/tipiracil. The smaller size of some of the subgroups may limit the conclusions that can be drawn, thus preventing an evaluation of other parameters that might impact on outcomes (such as lactate dehydrogenase levels). The exact definition of good and poor prognostic factors[@R12] may require further validation in a prospective cohort.

Conclusion {#s5}
==========

The current analysis shows that compared with poor prognosis patients treated with either trifluridine/tipiracil or placebo, and good prognosis patients treated with placebo, patients with GPCs treated with trifluridine/tipiracil (adequate organ function, ECOG PS 0--1, \<3 metastatic sites by RECIST tumour evaluation at randomisation, and ≥18 months from diagnosis of first metastasis) have an increased survival in terms of median OS and 6-month and 12 month survival rates. Treatment with trifluridine/tipiracil is effective and provides the majority of patients the opportunity to maintain ECOG PS and the possibility to receive further treatment options through the continuum of care.
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